Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ryvu TherapeuticsLTS:0RKT 66 PB Ratio is 16.93 as of Jul. 16, 2026, which is 219% above its 10-year median of 5.31. GuruFocus rates LTS:0RKT with a GF Score™ of 66/100 and a GF Value™ of zł86.63. The stock has 3 warning signs investors should review. Among 1,227 Biotechnology companies, Ryvu Therapeutics ranks worse than 82.89% on this metric.
The historical rank and industry rank for Ryvu Therapeutics's PB Ratio or its related term are showing as below:
LTS:0RKT'
s PB Ratio Range Over the Past 10 Years
Min: 2.23 Med: 5.31 Max: 14.3
Current: 8.95
During the past 13 years, Ryvu Therapeutics's highest PB Ratio was 14.30. The lowest was 2.23. And the median was 5.31.
LTS:0RKT's PB Ratio is ranked worse than 82.89% of 1227
companies
in the Biotechnology industry
Industry Median: 2.93
vs LTS:0RKT: 8.95
During the past 12 months, Ryvu Therapeutics's average Book Value Per Share Growth Rate was -65.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -50.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -23.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 3.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Ryvu Therapeutics was 133.20% per year. The lowest was -50.10% per year. And the median was 31.20% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Ryvu Therapeutics PB Ratio Related Terms
Ryvu Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Ryvu Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ryvu Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ryvu Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Ryvu Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Ryvu Therapeutics (LTS:0RKT) has a PB Ratio of 16.93 as of Jul. 16, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Ryvu Therapeutics and its competitors. This is 219% above median its historical median of 5.31. Over the past decade, Ryvu Therapeutics' PB Ratio has ranged from 2.23 to 14.30. According to the industry distribution chart, Ryvu Therapeutics ranks #1017 out of 1227 companies in the Biotechnology industry, placing it in the top 82.9%.
Is Ryvu Therapeutics' PB Ratio too high?
Ryvu Therapeutics' current PB Ratio of 16.93 is 219% above median its 10-year median of 5.31. Over the past 10 years, this metric has ranged from a low of 2.23 to a high of 14.30. The Biotechnology industry median PB Ratio is 2.93. Ryvu Therapeutics' value of 16.93 is 477.8% above this industry median. Based on the distribution chart, Ryvu Therapeutics ranks #1017 out of 1227 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ryvu Therapeutics has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Ryvu Therapeutics' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ryvu Therapeutics ranks #1017 out of 1227 companies for PB Ratio. This places Ryvu Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.93. Ryvu Therapeutics' value of 16.93 is 477.8% above this benchmark. Historically, Ryvu Therapeutics' own PB Ratio has ranged from 2.23 to 14.30 over the past decade. While the company's 10-year median is 5.31 vs. the industry median of 2.93, Ryvu Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ryvu Therapeutics's current PB Ratio of 16.93 is 477.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Ryvu Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ryvu Therapeutics's current PB Ratio is 16.93, which is 219% above median its own 10-year median of 5.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryvu Therapeutics stock overvalued right now?
Ryvu Therapeutics (LTS:0RKT) has a current PB Ratio of 16.93. The stock's GF Value™ is zł86.63, compared to a current price of zł30.25 — trading 65.1% below its estimated fair value. The current PB Ratio is 16.93, which is 219% above median its 10-year median of 5.31 and 477.8% above the Biotechnology industry median of 2.93. Ryvu Therapeutics' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Ryvu Therapeutics (LTS:0RKT), the current PB Ratio is 16.93 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ryvu Therapeutics (LTS:0RKT) Overvalued in 2026?
Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued.
The current stock price of zł30.25 is trading 65.1% below its estimated GF Value™ of zł86.63.
Key valuation signals for LTS:0RKT:
PB Ratio: 16.93 (219% above median its 10-year median of 5.31)
GF Value™: zł86.63 vs. price of zł30.25 (65.1% below fair value)
Industry Position: 477.8% above the Biotechnology median (#1017 of 1227)
No single metric tells the full story. See the LTS:0RKT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
66GF Score
Get the complete analysis for LTS:0RKT
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RKT has been successfully added to your 
